StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead (GILD) New Drug Filgotinib is Relatively Safe, But Black Box Still Likely - Baird
May 21, 2020 9:37 AM
Baird analyst Brian Skorney reiterated a Neutral rating and $75 price target on Gilead Sciences (NASDAQ: GILD) citing earnings stabilization ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Gilead Sciences (GILD), Galapagos NV (GLPG) Phase 2B/3 Trial of Filgotinib Met All Primary Endpoints
May 20, 2020 4:03 PM
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
May 20, 2020 4:03 PM